Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension.

Autor: Kim NH; Pulmonary Vascular Medicine, University of California San Diego, 9300 Campus Point Dr. MC7381, La Jolla, CA, 92037-7381, USA. h33kim@health.ucsd.edu., D'Armini AM; Department of Cardio-Thoracic and Vascular Surgery, Heart and Lung Transplantation and Pulmonary Hypertension Unit, Foundation IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, Italy., Howard LS; National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.; National Heart and Lung Institute, Imperial College London, London, UK., Jenkins DP; Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK., Jing ZC; State Key Lab of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Mayer E; Department of Thoracic Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany., Chamitava L; Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company, Statistical Decision Sciences, Allschwil, Switzerland., Lack G; Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company, Clinical Science, Allschwil, Switzerland., Rofael H; Janssen Research and Development, LLC, a Johnson & Johnson Company, Clinical Science, Titusville, NJ, USA., Solonets M; Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company, Global Medical Safety, Allschwil, Switzerland., Ghofrani HA; German Center for Lung Research (DZL), Giessen, Germany and University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany.; Department of Medicine, Imperial College London, London, UK.

Publikováno v: Pulmonary therapy [Pulm Ther] 2024 Nov 09. Date of Electronic Publication: 2024 Nov 09.

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.

Autor: Grünig E; Thoraxklinik at Heidelberg University Hospital and Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany., Jansa P; Charles University and General University Hospital, Prague, Czech Republic., Fan F; First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China., Hauser JA; Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Clinical Science, Allschwil, Switzerland., Pannaux M; Cytel Inc, Cambridge, Massachusetts, USA., Morganti A; Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Statistical Decision Science, Allschwil, Switzerland., Rofael H; Janssen Research and Development, LLC, Clinical Science, Titusville, New Jersey, USA., Chin KM; UT Southwestern Medical Center, Dallas, Texas, USA. Electronic address: kelly.chin@utsouthwestern.edu.

Publikováno v: Journal of the American College of Cardiology [J Am Coll Cardiol] 2024 Jan 30; Vol. 83 (4), pp. 473-484.

Effect of Ketamine on Cocaine-Induced Immunotoxicity in Rats.

Autor: Rofael, H. Z.¹, Turkall, R. M.^1,2, Abdel-Rahman, M. S.¹

Publikováno v: International Journal of Toxicology (Taylor & Francis). Sep/Oct2003, Vol. 22 Issue 5, p343. 16p.

Medications for attention-deficit/hyperactivity disorder in Japan: A retrospective cohort study of label compliance.

Autor: Fife D; Department of Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA., Voss EA; Department of Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA., Hardin J; Department of Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA., Rofael H; Established Products, Janssen Research & Development, LLC, Titusville, NJ, USA., Solomon ID; Established Products, Janssen Research & Development, LLC, Titusville, NJ, USA., Ryan PB; Department of Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA., Stang P; Department of Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA.

Publikováno v: Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2021 Sep; Vol. 41 (3), pp. 385-392. Date of Electronic Publication: 2021 Jun 28.

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.

Autor: Sperling R; Brigham and Women's Hospital, Boston, Massachusetts., Henley D; Janssen Research & Development LLC, Titusville, New Jersey.; Indiana University School of Medicine, Indianapolis., Aisen PS; Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles., Raman R; Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles., Donohue MC; Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles., Ernstrom K; Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles., Rafii MS; Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles., Streffer J; Janssen Research & Development LLC, Titusville, New Jersey.; Translational Medicine Neuroscience, UCB Biopharma SRL, Braine-l'Alleud, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Shi Y; Janssen Research & Development LLC, Titusville, New Jersey., Karcher K; Janssen Research & Development LLC, Titusville, New Jersey., Raghavan N; Janssen Research & Development LLC, Titusville, New Jersey., Tymofyeyev Y; Janssen Research & Development LLC, Titusville, New Jersey., Bogert J; Janssen Research & Development LLC, Titusville, New Jersey., Brashear HR; Janssen Research & Development LLC, Titusville, New Jersey.; Department of Neurology, University of Virginia, Charlottesville., Novak G; Janssen Research & Development LLC, Titusville, New Jersey., Thipphawong J; Janssen Research & Development LLC, Titusville, New Jersey., Saad ZS; Janssen Research & Development LLC, Titusville, New Jersey., Kolb H; Janssen Research & Development LLC, Titusville, New Jersey., Rofael H; Janssen Research & Development LLC, Titusville, New Jersey., Sanga P; Janssen Research & Development LLC, Titusville, New Jersey., Romano G; Janssen Research & Development LLC, Titusville, New Jersey.; Passage Bio, Philadelphia, Pennsylvania.

Publikováno v: JAMA neurology [JAMA Neurol] 2021 Mar 01; Vol. 78 (3), pp. 293-301.